A research-focused comparison of Retatrutide and Tirzepatide — receptor targets, mechanism, study findings, and how the triple agonist differs from the dual agonist.
Tirzepatide and Retatrutide are incretin-receptor agonists studied extensively in metabolic research. Tirzepatide is a dual agonist acting on the GIP and GLP-1 receptors. Retatrutide is a triple agonist that additionally targets the glucagon receptor. This comparison summarises their receptor pharmacology and the published research distinguishing them, for in-vitro research context only.
Tirzepatide binds and activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide retains GIP and GLP-1 receptor activity and adds glucagon receptor agonism — a triple-agonist profile investigated for additive effects on energy expenditure and substrate metabolism in research models.
In published trial literature, Retatrutide has been associated with larger reported changes in body-composition endpoints than dual agonists, attributed in part to glucagon-receptor engagement. Tirzepatide remains one of the most widely referenced dual incretin agonists in the research literature, with an extensive characterisation across metabolic study designs. Researchers should consult primary literature for endpoint-specific data.
Both compounds are supplied as lyophilised powder, reconstituted with bacteriostatic water before in-vitro use, and stored per peptide stability guidance. Each Neovia batch ships with an independent Certificate of Analysis. Both are sold strictly for laboratory research and not for human consumption.
All products sold by Neovia Peptides are strictly for in-vitro research and laboratory use only. Not intended for human or veterinary use, food additives, drugs, or cosmetics. By purchasing from this website, you agree that you understand and accept these terms.
